CAMP4 reports Q3 net loss $13.5M, completes IPO raising $82.1M, and signs BioMarin collaboration

Camp4 Therapeutics Corp

Q3 net loss $13.5M vs $11.7M in prior year; R&D $9.7M, G&A $3.8M.
Completed IPO in Oct 2024: 6.82M shares at $11.00, gross proceeds $82.1M (including partial underwriter option).
Entered strategic research collaboration with BioMarin valued at over $370M in milestones and royalties.
Phase 1 SAD portion completed; safety data expected Q1 2025, MAD biomarker data in H2 2025.
Cash $2.5M as of Sep 30, 2024; pro forma with IPO proceeds well-positioned to support development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.